Twist Bioscience Corporation
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $118.4M | $110.7M | $103.7M | $99.0M | $96.1M | $92.8M | $88.7M | $84.7M |
| Cost of Revenue | $55.9M | $53.6M | $49.7M | $48.2M | $44.8M | $46.8M | $45.9M | $46.5M |
| Gross Profit | $62.5M | $57.1M | $54.0M | $50.8M | $51.3M | $46.0M | $42.8M | $38.2M |
| Gross Margin | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 45.1% |
| Operating Expenses | ||||||||
| Research & Development | $18.0M | $19.7M | $17.1M | $17.0M | $18.0M | $23.9M | $21.3M | $21.1M |
| SG&A Expense | $80.7M | $76.1M | $69.7M | $63.8M | $63.4M | $63.7M | $56.2M | $53.1M |
| Operating Income | $-36.3M | $-45.9M | $-32.9M | $-29.9M | $-30.1M | $-41.6M | $-34.6M | $-36.0M |
| Operating Margin | -30.6% | -41.4% | -31.7% | -30.2% | -31.4% | -44.8% | -39.1% | -42.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-34.7M | $-44.0M | $-30.3M | $-26.9M | $20.6M | $-39.2M | $-31.5M | $-34.8M |
| Income Tax Expense | $311.0K | $43.0K | $253.0K | $256.0K | $191.0K | $175.0K | $97.0K | $-96.0K |
| Net Income | $-35.1M | $-44.0M | $-30.5M | $-27.1M | $20.4M | $-39.3M | $-31.6M | $-34.7M |
| Net Margin | -29.6% | -39.8% | -29.4% | -27.4% | 21.2% | -42.4% | -35.6% | -40.9% |
| EPS (Basic) | $-0.56 | $-0.71 | $-0.50 | $-0.45 | $0.34 | $-0.66 | $-0.53 | $-0.59 |
| EPS (Diluted) | $-0.56 | $-0.71 | $-0.50 | $-0.44 | $0.33 | $-0.66 | $-0.53 | $-0.59 |
| Shares Outstanding (Basic) | 62.4M | 61.7M | 61.1M | 59.8M | 60.0M | 59.6M | 59.2M | 58.0M |
| Shares Outstanding (Diluted) | 62.4M | 61.7M | 61.1M | 59.8M | 61.2M | 59.6M | 59.2M | 58.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |